Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy-Reference-Cited by-同舟云学术

Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy

Published:2011-10-15 Issue:4 Volume:61 Page:535-547
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Fowler Daniel W.,Copier John,Wilson Natalie,Dalgleish Angus G.,Bodman-Smith Mark D.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://www.springerlink.com/index/pdf/10.1007/s00262-011-1121-4

Reference46 articles.

1. Herr HW, Morales A (2008) History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 179(1):53–56

2. Maraveyas A, Baban B, Kennard D, Rook GA, Westby M, Grange JM, Lydyard P, Stanford JL, Jones M, Selby P, Dalgleish AG (1999) Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 10(7):817–824

3. O’Brien ME, Saini A, Smith IE, Webb A, Gregory K, Mendes R, Ryan C, Priest K, Bromelow KV, Palmer RD, Tuckwell N, Kennard DA, Souberbielle BE (2000) A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 83(7):853–857

4. Eaton JD, Perry MJ, Nicholson S, Guckian M, Russell N, Whelan M, Kirby RS (2002) Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 89(1):19–26

5. Patel PM, Sim S, O’Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey P, Dalgleish A, Johnston C, Banks RE, Selby PJ (2008) An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer 44(2):216–223

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. γδ T cells: Major advances in basic and clinical research in tumor immunotherapy;Chinese Medical Journal;2023-08-18

2. BCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and γδ T-cells that can be further expanded in vitro;OncoImmunology;2022-12-22

3. Immune-modulating Effects of Mycobacteria;2022-08-03

4. γδ T Cells in the Tumor Microenvironment—Interactions With Other Immune Cells;Frontiers in Immunology;2022-07-11

5. Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy;Cancers;2022-06-18